Entasis Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 47
Employees
  • Stock Symbol
  • ETTX
Stock Symbol
  • Share Price
  • $3.01
  • (As of Thursday Closing)

Entasis Therapeutics General Information

Description

Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Boston BioHub
  • 35 Gatehouse Drive
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Entasis Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Entasis Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.01 $2.84 $1.75 - $9.25 $82.1M 27.3M 184K -$3.50

Entasis Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 55,034 19,181 (40,705)
Revenue 7,000 7,000 5,000 0
EBITDA (46,228) (44,494) (32,706) (29,754)
Net Income (46,189) (43,850) (32,952) (29,923)
Total Assets 56,464 51,034 89,274 58,794
Total Debt 1,597 1,827 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Entasis Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial

Entasis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, develop
Pharmaceuticals
Waltham, MA
47 As of 2019
00000
000000000 00000

000000 0

ed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nost
0000000000000
San Diego, CA
00 As of 0000
00000
00000000000 00000

00000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Durham, NC
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Entasis Therapeutics Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cidara Therapeutics Formerly VC-backed San Diego, CA 00 00000 00000000000 00000
00000000 Formerly VC-backed Durham, NC 00 00000 000000000 00000
00000000 000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
0000000000 Formerly VC-backed Yonkers, NY 00 00000 000000000 00000
0000000000 0000000 Formerly PE-Backed Watertown, MA 00 00000 000000&0 00000
You’re viewing 5 of 37 competitors. Get the full list »

Entasis Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Manoussos Perros Chief Executive Officer & Founder
Michael Gutch Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ruben Tommasi Ph.D Chief Scientific Officer
John Mueller Ph.D Executive
David Altarac Chief Medical Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Entasis Therapeutics Board Members (11)

Name Representing Role Since
David Hastings Self Board Member 000 0000
Gregory Norden Self Board Member 000 0000
Heather Behanna Ph.D Sofinnova Investments Board Member 000 0000
Heather Preston MD TPG Biotech Board Member 000 0000
Nicholas Galakatos Ph.D Blackstone Life Sciences Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Entasis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Entasis Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Entasis Therapeutics‘s full profile, request access.

Request a free trial